The United Kingdom and the United States have secured a significant trade agreement that will maintain no import taxes on British medicine exports going into the US market.
Key Provisions of the Accord
In exchange for the tariff guarantee, the UK has committed to raise spending on drugs through the NHS. This pledge guarantees that import taxes on these key products will stay at zero for a timeframe of three years.
This deal is in response to earlier warnings to significantly raise duties on branded pharmaceutical imports, with increases mentioned reaching 100%.
"This deal with the United Kingdom strengthens the international landscape for new treatments and brings long-overdue balance to American-British pharmaceutical trade," a statement noted.
Commercial Importance
Pharmaceuticals are one of the UK's largest export categories to the US, which is clearly the primary market for large companies like GSK and AstraZeneca.
Export figures indicate that in the 12 months to the end of last September, the UK exported medicines valued at £11.1bn to the US. This amount accounted for nearly one-fifth of all goods exports in that timeframe.
"This agreement safeguards employment, stimulates funding and sets the stage for the UK to establish itself as a worldwide center for life sciences," a government official remarked.
Key NHS Changes
The pact entails several key changes from the British government:
- Price Threshold Increase: The UK will increase the cost ceiling at which it deems new medicines to be too expensive by 25%.
- Increased NHS Spending: There is a aim to increase total health service expenditure on medicines from 0.3% of GDP to 0.6% over the coming ten years.
- Refund Ceiling: The percentage pharmaceutical firms must refund to the NHS to control costs will be capped at fifteen percent. In the past, rebates topped 20%.
Broader Context
This agreement takes place against a protracted dispute between the drug companies and the UK government over spending levels and approval rates.
This friction were exacerbated by claims that American customers were paying a premium for the identical medicines than patients in the Britain and the EU.
Over the last 18 months, several significant drug company projects in the UK have been delayed or cancelled, while multi-billion-dollar investments have been directed toward American operations.
One official stated that the NHS had to spend more on drugs, noting that its spending on drugs had declined as a share of its total funding over the past decade.
